We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fixed Regimen Treatment in Unselected Naïve Patients Cohort with Neovascular Age-Related Macular Degeneration.
- Authors
Casaroli-Marano, Ricardo P.; Bernal-Morales, Carolina; Chamorro-López, Lillian; Dotti-Boada, Marina; Figueroa-Vercellino, Juan P.; Alforja, Socorro
- Abstract
The current treatment of neovascular age-related macular degeneration (nAMD) generates an excessive care pressure in the public health system. The search for a satisfactory treatment regimen, whose anatomical and functional stability may be achieved, is a challenge and a goal to be reached. We analyzed the outcomes in a patient cohort under fixed regimen treatment with intravitreal aflibercept (IVA). A retrospective study, with at least 1-year follow-up, in consecutive treated unselected naïve patients was carried out. Standard protocol was performed and evaluated at baseline, month 4 (after loading dose, LD), and month 12 (after fixed bimonthly regimen). One hundred six patients (123 eyes) aged 80.3 ± 7.7 years were included, receiving 6.8 ± 0.7 IVA. Visual acuity gain after LD was 5.5 ± 12.0 letters (p < 0.0001). At month 12, 23 eyes (18.7%) gained ≥15 letters and 58 (47.1%) had best-corrected visual acuity ≥20/40 (70 letters). The improvement in visual acuity was lower in patients with polypoidal choroidal vasculopathy (+4.9 ± 18.1 letters; p = 0.2544) and somewhat higher in patients with retinal angiomatous proliferation (+5.4 ± 12.3 letters; p = 0.0373). Dry macula was present in only 9.8% of cohort at baseline vs. 69.7% at month 12 (p < 0.0001). Atrophy was the most observed complication and related to the elderly patients. The average of follow-up visits was 3 ± 0.5. Functional and anatomical improvement were observed with IVA in a fixed bimonthly regimen treatment after LD, with results maintained up to one year with a good compliance. The fixed bimonthly regimen optimized patient management and logistic issues.
- Subjects
VASCULAR endothelial growth factor antagonists; CELL proliferation; CONFIDENCE intervals; INJECTIONS; MEDICAL appointments; RECOMBINANT proteins; RETINAL degeneration; VISUAL acuity; RETROSPECTIVE studies; PATHOLOGIC neovascularization; ODDS ratio
- Publication
Journal of Ophthalmology, 2020, p1
- ISSN
2090-004X
- Publication type
Article
- DOI
10.1155/2020/8848336